Postmarketing surveillance of new food ingredients: Results from the program with the fat replacer olestra

Gregory S. Allgood, David J. Kuter, Kevin T. Roll, Steve L. Taylor, Nora L. Zorich

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Market introduction of savory snacks containing olestra offered an opportunity to evaluate the safety of olestra in a free-living population and thereby compare the outcome to the previously established safety profile determined in clinical trials in which subjects were required to eat predetermined amounts at prescribed intervals. Therefore, a multifaceted postmarketing surveillance program was designed to evaluate consumer experience and safety of olestra in the marketplace. Customer comments were solicited through toll-free telephone numbers. Collected data were evaluated by both internal and external medical experts. About 10% of toll-free telephone calls reported health effects, most of which were gastrointestinal (GI) in nature. Clinical studies were designed and conducted to determine potential GI effects under the range of consumption patterns reported by toll-free calls. Health effects reported were those found commonly in the general population and analyses of the data found no biological reason to conclude that serious or meaningful health effects were the result of olestra consumption.

Original languageEnglish (US)
Pages (from-to)224-233
Number of pages10
JournalRegulatory Toxicology and Pharmacology
Volume33
Issue number2
DOIs
StatePublished - Apr 2001

Fingerprint

Fats
Food
Health
Telephone
Safety
Satureja
Snacks
Population
Clinical Trials
sucrose polyester

Keywords

  • Allergy
  • Fat consumption
  • Fat substitute
  • Gastrointestinal
  • Olean
  • Olestra
  • Postmarketing surveillance
  • Procter & Gamble
  • Vitamin K
  • Warfarin

ASJC Scopus subject areas

  • Toxicology

Cite this

Postmarketing surveillance of new food ingredients : Results from the program with the fat replacer olestra. / Allgood, Gregory S.; Kuter, David J.; Roll, Kevin T.; Taylor, Steve L.; Zorich, Nora L.

In: Regulatory Toxicology and Pharmacology, Vol. 33, No. 2, 04.2001, p. 224-233.

Research output: Contribution to journalArticle

Allgood, Gregory S. ; Kuter, David J. ; Roll, Kevin T. ; Taylor, Steve L. ; Zorich, Nora L. / Postmarketing surveillance of new food ingredients : Results from the program with the fat replacer olestra. In: Regulatory Toxicology and Pharmacology. 2001 ; Vol. 33, No. 2. pp. 224-233.
@article{7c973868d7bf4f9d9abc60dded735f0c,
title = "Postmarketing surveillance of new food ingredients: Results from the program with the fat replacer olestra",
abstract = "Market introduction of savory snacks containing olestra offered an opportunity to evaluate the safety of olestra in a free-living population and thereby compare the outcome to the previously established safety profile determined in clinical trials in which subjects were required to eat predetermined amounts at prescribed intervals. Therefore, a multifaceted postmarketing surveillance program was designed to evaluate consumer experience and safety of olestra in the marketplace. Customer comments were solicited through toll-free telephone numbers. Collected data were evaluated by both internal and external medical experts. About 10{\%} of toll-free telephone calls reported health effects, most of which were gastrointestinal (GI) in nature. Clinical studies were designed and conducted to determine potential GI effects under the range of consumption patterns reported by toll-free calls. Health effects reported were those found commonly in the general population and analyses of the data found no biological reason to conclude that serious or meaningful health effects were the result of olestra consumption.",
keywords = "Allergy, Fat consumption, Fat substitute, Gastrointestinal, Olean, Olestra, Postmarketing surveillance, Procter & Gamble, Vitamin K, Warfarin",
author = "Allgood, {Gregory S.} and Kuter, {David J.} and Roll, {Kevin T.} and Taylor, {Steve L.} and Zorich, {Nora L.}",
year = "2001",
month = "4",
doi = "10.1006/rtph.2001.1460",
language = "English (US)",
volume = "33",
pages = "224--233",
journal = "Regulatory Toxicology and Pharmacology",
issn = "0273-2300",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Postmarketing surveillance of new food ingredients

T2 - Results from the program with the fat replacer olestra

AU - Allgood, Gregory S.

AU - Kuter, David J.

AU - Roll, Kevin T.

AU - Taylor, Steve L.

AU - Zorich, Nora L.

PY - 2001/4

Y1 - 2001/4

N2 - Market introduction of savory snacks containing olestra offered an opportunity to evaluate the safety of olestra in a free-living population and thereby compare the outcome to the previously established safety profile determined in clinical trials in which subjects were required to eat predetermined amounts at prescribed intervals. Therefore, a multifaceted postmarketing surveillance program was designed to evaluate consumer experience and safety of olestra in the marketplace. Customer comments were solicited through toll-free telephone numbers. Collected data were evaluated by both internal and external medical experts. About 10% of toll-free telephone calls reported health effects, most of which were gastrointestinal (GI) in nature. Clinical studies were designed and conducted to determine potential GI effects under the range of consumption patterns reported by toll-free calls. Health effects reported were those found commonly in the general population and analyses of the data found no biological reason to conclude that serious or meaningful health effects were the result of olestra consumption.

AB - Market introduction of savory snacks containing olestra offered an opportunity to evaluate the safety of olestra in a free-living population and thereby compare the outcome to the previously established safety profile determined in clinical trials in which subjects were required to eat predetermined amounts at prescribed intervals. Therefore, a multifaceted postmarketing surveillance program was designed to evaluate consumer experience and safety of olestra in the marketplace. Customer comments were solicited through toll-free telephone numbers. Collected data were evaluated by both internal and external medical experts. About 10% of toll-free telephone calls reported health effects, most of which were gastrointestinal (GI) in nature. Clinical studies were designed and conducted to determine potential GI effects under the range of consumption patterns reported by toll-free calls. Health effects reported were those found commonly in the general population and analyses of the data found no biological reason to conclude that serious or meaningful health effects were the result of olestra consumption.

KW - Allergy

KW - Fat consumption

KW - Fat substitute

KW - Gastrointestinal

KW - Olean

KW - Olestra

KW - Postmarketing surveillance

KW - Procter & Gamble

KW - Vitamin K

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=0034997057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034997057&partnerID=8YFLogxK

U2 - 10.1006/rtph.2001.1460

DO - 10.1006/rtph.2001.1460

M3 - Article

C2 - 11350205

AN - SCOPUS:0034997057

VL - 33

SP - 224

EP - 233

JO - Regulatory Toxicology and Pharmacology

JF - Regulatory Toxicology and Pharmacology

SN - 0273-2300

IS - 2

ER -